UnitedHealth's Medical Membership Rises: Can It Maintain the Momentum?

UnitedHealth (UNH) has seen a 5% increase in medical membership in 2024 and a further 2% in Q1 2025, reaching 50.1 million members, driven by its vertically integrated model; however, the company suspended its 2025 guidance due to higher-than-expected Medicare Advantage costs. This contrasts with membership declines at competitors Humana (HUM) and Elevance Health (ELV), but UNH shares have underperformed the industry year-to-date, and 2025 earnings are projected to decline 18.7%.

Analysis

UnitedHealth Group (UNH) has demonstrated robust medical membership growth, increasing 5% in 2024 and an additional 2% in Q1 2025 to reach 50.1 million members, primarily driven by its vertically integrated model combining insurance (UnitedHealthcare) with care delivery and pharmacy services (Optum). This growth contrasts with competitors Humana (HUM) and Elevance Health (ELV), which reported year-over-year membership declines of 8.3% and 0.5% respectively in Q1 2025, with both also citing rising costs. Despite its membership gains, UNH suspended its full-year 2025 guidance due to unexpectedly high medical costs in its Medicare Advantage segment during Q1 2025. The return of CEO Steve Hemsley signals a renewed focus on operational efficiency, pricing, risk adjustment, and care coordination to address these cost pressures. UNH's stock has significantly underperformed, declining 39.3% year-to-date compared to the industry's 29.2% fall. The company trades at a forward price-to-earnings ratio of 12.58, above the industry average of 11.58, even as the Zacks Consensus Estimate for its 2025 earnings indicates an 18.7% year-over-year decrease. Compounding these concerns, UNH currently holds a Zacks Rank #5 (Strong Sell), reflecting significant headwinds.

Key Decisions for Investors

• Investors should exercise caution given UNH's suspended 2025 guidance, significant Medicare Advantage cost pressures, and a projected 18.7% decline in 2025 earnings, despite recent membership growth.
• Monitor closely the new CEO's initiatives to manage costs, improve pricing, and navigate the evolving Medicare Advantage landscape, particularly ahead of the 2026 CMS rate changes.
• Re-evaluate positions considering the stock's year-to-date underperformance of 39.3%, its premium forward P/E ratio relative to the industry, and the current Zacks Rank #5 (Strong Sell), which signals potential further downside or a challenging recovery period.